Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson's disease

✍ Scribed by Vicki Shanker; Mark Groves; Gary Heiman; Christina Palmese; Rachel Saunders-Pullman; Laurie Ozelius; Deborah Raymond; Susan Bressman

• Publisher: John Wiley and Sons
• Year: 2011
• Tongue: English
• Weight: 110 KB
• Volume: 26
• Category: Article
• ISSN: 0885-3185
• DOI: 10.1002/mds.23746

✦ Synopsis

Abstract

The behavioral and cognitive features of the leucine‐rich repeat kinase G2019S mutation in Parkinson's disease in the Ashkenazi Jewish population are not well described; therefore, we sought to more systematically characterize these features using a semistructured psychiatric interview and neuropsychological testing. Twenty‐one Ashkenazi Jewish patients having the leucine‐rich repeat kinase G2019S mutation were compared with age‐ and sex‐matched Ashkenazi Jewish patients with Parkinson's disease without mutations. Although overall rates of affective disorders were not greater in mutation carriers, the carriers exhibited a 6‐fold increased risk of premorbid affective disorders (odds ratio, 6.0; P = .10), as determined by the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders–IV. Of interest, we identified 2 leucine‐rich repeat kinase carriers with bipolar disorder; no mutation‐negative subjects had this diagnosis. Performance on the Hopkins Verbal Learning Test–Revised, Judgment of Line Orientation, and Frontal Assessment Battery was consistent with previous reports and did not differ between groups. Study findings suggest a possible association between premorbid mood disorders and leucine‐rich repeat kinase Parkinson's disease, warranting further evaluation. © 2011 Movement Disorder Society